The UK Supreme Court has invalidated Pfizer’s second medical use patent on Lyrica (pregabalin) in the treatment of neuropathic pain. As well as being a major blow for the Pfizer, lawyers say the ruling could make it more difficult for companies to take out and defend life science patents in future.
“The Supreme Court’s decision is potentially bad news for patentees, not least in the biotechnology and pharmaceutical fields,” said Nick...





